

Right to Die (End of Life Option Act)

Operational Manual –

Purpose	
To recognize the rights of qualified residents to make informed decisions regarding end of life treatment options and facilitate transfer to a participating provider.	
Policy	
The Company has elected to opt out of participation in the End of Life Option Act.	
Procedure	
<ol style="list-style-type: none">I. The Company will provide applicable employees, independent contractors and affiliated healthcare providers with HSP – 06 – Form A – Notice of Prohibition to notify these individuals that the Company has opted out of participation in the End of Life Option Act (EOLOA) upon hire or the date that the independent contractor/affiliated healthcare provider first provides services to patient’s of the Company.<ol style="list-style-type: none">A. The Company will post this policy on its website to satisfy the requirement to provide annual notice of participation in EOLOA to its employees, applicable independent contractors and affiliated healthcare providers.II. During admission, nursing staff will inquire whether the patient has initiated the process for obtaining an “aid-in-dying drug”.<ol style="list-style-type: none">A. “Aid-in-dying drug” means a drug determined and prescribed by a physician for a qualified individual, which the qualified individual may choose to self-administer to bring about his or her death due to a terminal disease.B. If the patient has initiated a request under EOLOA, nursing staff will refer the resident to the Director of Patient Care Services.C. The Director of Patient Care Services or Executive Director will notify the resident that the Company has opted out of participation in EOLOA and will assist the patient with finding alternative placement if he/she wishes to proceed with the EOLOA process.III. If after the time of admission, a patient requests to exercise his/her right under EOLOA, follow steps II. B. and II. C. above.IV. The Company will document notification to the patient of the Company’s non-participation in EOLOA and attempts to facilitate a transfer to accommodate the patient’s treatment preferences.V. Upon transfer, the documentation of the patient’s request for the aid-in-dying drug will be provided to the patient and receiving healthcare provider.	
References	
Sources: CAL. HEALTH & SAFETY CODE §§ 443.	
Forms: HSP – 06 – Form A – Notice of Prohibition	
Employee(s): Executive Director, Medical Director, Attending Physicians, Nursing Staff,	
Version No. 3.0	Date Revised: January 5, 2022

